Home › Compare › ACPIF vs ABBV
ACPIF yields 0.08% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ACPIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ACPIF + ABBV for your $10,000?
Acen Corporation, together with its subsidiaries, engages in the power generation and trading; and oil and mineral exploration, development, and production activities in the Philippines and internationally. It operates and maintains 81 megawatts (MW) and 52MW wind farms in Ilocos Norte; a 54MW wind farm in Guimaras; a 40MW wind farm in Binh Thuan Province, Vietnam; a 252MW wind farm in Quang Binh Province, Vietnam; a 88MW wind farm in Ninh Thuan, Vietnam; a 75 MW wind farm in South Sulawesi, Indonesia; 80MWdc, 18MWdc, and 45MWdc solar power farms in Negros Occidental; a 120MWdc solar power farm in Alaminos, Laguna; a 63MWdc solar power farm in Palauig, Zambales; a 80MWdc solar power plants in Dak Lak and Khanh Hoa, Vietnam; and 140MWdc and 70MWdc solar power farms in Rajasthan and Gujarat, India. The company also owns and operates a 244MW coal thermal project located in Batangas; 108MW diesel plant in Olongapo City; 20MW diesel power plant in La Union; 48MW diesel plant in Bulacan; 24MW diesel power barge plant in Iloilo; 150MW diesel plant in Pililia, Rizal; 32MW geothermal plant in Santo Tomas, Batangas; and 663MW geothermal plant in West Java, Indonesia. It also engages in the leasing and land development activities; trading of electricity in the wholesale electricity spot market; distribution of petroleum products; financing activities; and advisory/consultancy activities. The company was formerly known as AC Energy Corporation and changed its name to Acen Corporation in July 2022. The company was incorporated in 1969 and is based in Makati City, the Philippines. Acen Corporation is a subsidiary of AC Energy and Infrastructure Corporation.
Full ACPIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.